The European drug authority recommends refusal of marketing authorization due to evidence gaps in quality and efficacy.

Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the ...

Q2 2025 Earnings Call Transcript July 30, 2025 Anika Therapeutics, Inc. reports earnings inline with expectations. Reported ...

Non-GAAP adjusted EBITDA for the quarter ended June 30, 2025 was $13.4 million, or 21% of net revenue, compared to $6.3 million, or 12% of net revenue, for the second quarter of 2024. A table ...

Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million ...

Anika Therapeutics' (NASDAQ:ANIK) stock falls as the company's cartilage repair product Hyalofast misses key trial endpoints ...

Shares of Anika Therapeutics hit a 52-week low after it said its Hyalofast cartilage-repair product didn't meet its co-primary endpoints in a Phase III study. The stock was recently down 24% to $8.43 ...

Announcing a new article publication for BIO Integration journal. Osteochondral damage is primarily caused by degeneration of articular cartilage due to trauma, degenerative injury.

For nearly three decades, Mayo Clinic researcher Christopher Evans, Ph.D., has pushed to expand gene therapy beyond its ...

When surgeons repair tissues, they're currently limited to mechanical solutions such as sutures and staples, which can cause their own damage, or meshes and glues that may not adequately bond with ...